BiomX Announces a Mandatory Unit Separation
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing phage therapies targeting specific pathogenic bacteria, has announced a mandatory separation of its units (PHGE.U). Each unit consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American.
Key points:
- Unit holders will receive the underlying shares of Common Stock and Warrants
- The separation is automatic, requiring no action from unit holders
- Warrants will expire on October 28, 2024
- Each warrant allows purchase of one-half share at $115 per share
- Post-separation, Common Stock will trade under the symbol PHGE
BiomX Inc. (NYSE American: PHGE), una compagnia in fase clinica che sviluppa terapie a base di fagi mirate a batteri patogeni specifici, ha annunciato una separazione obbligatoria delle sue unità (PHGE.U). Ogni unità è composta da un'azione di Common Stock e un warrant per l'acquisto di una metà di un'azione di Common Stock. La separazione avverrà il 25 ottobre 2024 circa, dopo di che le unità non verranno più scambiate sul NYSE American.
Punti chiave:
- I detentori delle unità riceveranno le azioni sottostanti di Common Stock e Warrant
- La separazione è automatica e non richiede alcuna azione da parte dei detentori delle unità
- I warrant scadranno il 28 ottobre 2024
- Ogni warrant consente l'acquisto di una metà azione a $115 per azione
- Dopo la separazione, il Common Stock verrà scambiato con il simbolo PHGE
BiomX Inc. (NYSE American: PHGE), una empresa en etapa clínica que desarrolla terapias con fagos dirigidas a bacterias patógenas específicas, ha anunciado una separación obligatoria de sus unidades (PHGE.U). Cada unidad consta de una acción de Common Stock y un warrant para comprar media acción de Common Stock. La separación ocurrirá el 25 de octubre de 2024, después de lo cual las unidades ya no se negociarán en el NYSE American.
Puntos clave:
- Los tenedores de unidades recibirán las acciones subyacentes de Common Stock y Warrants
- La separación es automática y no requiere ninguna acción por parte de los tenedores de unidades
- Los warrants vencerán el 28 de octubre de 2024
- Cada warrant permite la compra de media acción a $115 por acción
- Después de la separación, el Common Stock se negociará bajo el símbolo PHGE
바이옴엑스 주식회사 (NYSE American: PHGE), 특정 병원성 박테리아를 겨냥한 파지 요법을 개발하는 임상 단계 회사는 자사 유닛(PHGE.U)의 의무 분리를 발표했습니다. 각 유닛은 보통주 1주와 보통주의 절반을 구매할 수 있는 워런트 1개로 구성됩니다. 분리는 2024년 10월 25일 경에 발생하며, 그 이후 유닛은 NYSE American에서 거래되지 않습니다.
주요 사항:
- 유닛 보유자는 기본 보통주와 워런트를 받게 됩니다.
- 분리는 자동으로 진행되며 유닛 보유자가 아무런 조치를 취할 필요가 없습니다.
- 워런트는 2024년 10월 28일에 만료됩니다.
- 각 워런트는 한 주당 $115에 반주를 구매할 수 있게 해줍니다.
- 분리 이후, 보통주는 심볼 PHGE로 거래됩니다.
BiomX Inc. (NYSE American: PHGE), une entreprise en phase clinique développant des thérapies phagiques ciblant des bactéries pathogènes spécifiques, a annoncé une séparation obligatoire de ses unités (PHGE.U). Chaque unité se compose d'une action de Common Stock et d'un warrant pour l'achat d'une demi-action de Common Stock. La séparation aura lieu autour du 25 octobre 2024, après quoi les unités ne seront plus négociées sur le NYSE American.
Points clés :
- Les détenteurs d'unités recevront les actions sous-jacentes de Common Stock et les Warrants
- La séparation est automatique et ne nécessite aucune action de la part des détenteurs d'unités
- Les Warrants expireront le 28 octobre 2024
- Chaque warrant permet l'achat d'une demi-action à 115 $ par action
- Après la séparation, le Common Stock sera négocié sous le symbole PHGE
BiomX Inc. (NYSE American: PHGE), ein Unternehmen in der klinischen Phase, das Phagentherapien zur Bekämpfung spezifischer pathogener Bakterien entwickelt, hat eine obligatorische Trennung seiner Einheiten (PHGE.U) angekündigt. Jede Einheit besteht aus einer Aktie der Common Stock und einem Warrant zum Kauf von einem halben Anteil an der Common Stock. Die Trennung erfolgt voraussichtlich am 25. Oktober 2024, nach dem Zeitpunkt werden die Einheiten nicht mehr an der NYSE American gehandelt.
Wichtige Punkte:
- Einheiteninhaber erhalten die zugrunde liegenden Aktien der Common Stock und Warrants
- Die Trennung erfolgt automatisch und erfordert keine Maßnahmen der Einheiteninhaber
- Warrants verfallen am 28. Oktober 2024
- Jeder Warrant ermöglicht den Kauf von einem halben Anteil zu $115 pro Aktie
- Nach der Trennung wird die Common Stock unter dem Symbol PHGE gehandelt
- Mandatory unit separation may simplify the company's capital structure
- Automatic process requires no action from unit holders, potentially reducing investor confusion
- Warrants expire shortly after the mandatory separation on October 28, 2024, potentially limiting investor options
- High warrant exercise price of $115 per share may be unattractive to some investors
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of
On or about October 25, 2024, the Units will be mandatorily separated and will no longer trade on the NYSE American (the “Mandatory Unit Separation”). In the separation, Unit holders will receive the number of shares of Common Stock and Warrants underlying such Units. This is a mandatory and automatic separation, and no action is required by the holders of Units. The Warrants will expire on October 28, 2024.
Following the Mandatory Unit Separation, the shares of Common Stock underlying the Units will trade under the symbol PHGE with the other existing shares of the Company’s Common Stock.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Contacts:
BiomX, Inc.
Ben Cohen
benc@biomx.com
CORE IR
Peter Seltzberg
ir-biomx@biomx.com
FAQ
When will BiomX (PHGE) implement the mandatory unit separation?
What will PHGE unit holders receive after the mandatory separation?
What is the expiration date for the PHGE warrants?
What is the exercise price for the PHGE warrants?
Under what symbol will PHGE Common Stock trade after the unit separation?
